Download PDF
1 / Pages

Other users also viewed these articles

Projection of the clinical and economic burden of chronic kidney disease between 2022 and 2027 in Spain: Results of the Inside CKD project Juan F. Navarro González; Alberto Ortiz; Ana Cebrián Cuenca; Marta Moreno Barón; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;
Nefrologia (English Version). 2024;44:807-17
Preclinical gout is common in the patient with stage 3¿5 chronic kidney disease. Relevance of musculoskeletal ultrasound Enrique Calvo-Aranda; Laura Barrio Nogal; Boris Anthony Blanco Caceres; Diana Peiteado; Marta Novella-Navarro; Eugenio De Miguel; Jaime Arroyo Palomo; Roberto Alcázar Arroyo; Juan Antonio Martín Navarro; Milagros Fernandez Lucas; Martha Elizabeth Diaz Dominguez; Marco Antonio Vaca Gallardo; Elda Besada Estevez; Leticia Lojo Oliveira;
Nefrologia (English Version). 2024;44:877-84
Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis Juan Francisco Navarro-González; Alberto Ortiz; Ana Cebrián Cuenca; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;
Nefrologia (English Version). 2024;44:857-67